Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02132676
Other study ID # IIR 15-321
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 25, 2016
Est. completion date July 30, 2019

Study information

Verified date August 2020
Source VA Office of Research and Development
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to evaluate the effectiveness of a peer-to-peer program (P2P) in addition to Shared Medical Appointments (SMAs) compared to SMAs alone for the treatment of diabetes in five VA health systems, and to study the implementation process in order to gather information required to disseminate the program more broadly in the VHA system.


Description:

Providers are often unable to communicate as frequently as needed with diabetes patients who have poor risk factor control and face significant self-management challenges. Moreover, many VA patients face barriers to attending frequent face-to-face visits. This project will evaluate the implementation of a novel program found in a recent VA randomized, controlled trial to significantly improve VA patients' diabetes-specific social support, insulin starts, and glycemic control compared to usual nurse care management. The program uses periodic group sessions in conjunction with calls between paired patients with diabetes to promote more effective care management as well as peer-to-peer (P2P) communication among diabetes patients who both have poor glycemic control and are working on similar care goals. "Peer buddies" are encouraged to talk by phone at least weekly to provide mutual support and share their progress on meeting their self-management goals. The goal of this service is to enhance the effect of shared medical appointments (SMAs), a service model demonstrated to be effective in improving outcomes among patients with diabetes and other chronic conditions and now being widely implemented in VA. Based on the success of the efficacy trial of this intervention, the investigators now seek to evaluate a wider-scale implementation of this program. During implementation of the P2P program in conjunction with shared medical appointments (SMAs) in five diverse VA facilities, the investigators will evaluate the effectiveness of SMAs alone and SMAs+P2P compared to usual care, and study the implementation process in order to gather information required to disseminate the program more broadly in Veterans Health Administration (VHA).


Recruitment information / eligibility

Status Completed
Enrollment 1536
Est. completion date July 30, 2019
Est. primary completion date June 28, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

Veterans enrolled into diabetes Shared Medical Appointments (SMAs) at participating sites, and a random subset of those meeting criteria for diabetes SMAs who have not yet participated:

- Veteran receiving care at a participating VA Medical Center

- Meets at least one of the following criteria in the past 2 years;

- at least 1 VA hospitalization with a diabetes-related International Classification Of Diseases-9 (ICD-9) code,

- at least 2 VA outpatient visits with a diabetes-related ICD-9 code, or

- At least 1 VA prescription for a glucose control medication (insulin or oral agent) or monitoring supplies

- Poor glycemic control, indicated by a HbA1c in the past 6 months or:

- at least 7.5% if age <70, or

- at least 8% if age 70+

- Has a current address and telephone number listed in VA databases

- Is competent to provide informed consent

- Can communicate in English and by telephone

- Able to participate in an outpatient program

Exclusion Criteria:

For no intervention control group:

- Active substance abuse disorder (smoking cigarettes is not an exclusion)

- Serious psychiatric illness (bipolar disorder, dementia, schizophrenia, or personality disorders)

- Terminally ill

- Prisoner

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States VA Ann Arbor Healthcare System, Ann Arbor, MI Ann Arbor Michigan
United States VA Palo Alto Health Care System, Palo Alto, CA Palo Alto California
United States Providence VA Medical Center, Providence, RI Providence Rhode Island
United States VA Northern California Health Care System, Mather, CA Sacramento California
United States VA Connecticut Healthcare System West Haven Campus, West Haven, CT West Haven Connecticut

Sponsors (1)

Lead Sponsor Collaborator
VA Office of Research and Development

Country where clinical trial is conducted

United States, 

References & Publications (2)

Heisler M, Burgess J, Cass J, Chardos JF, Guirguis AB, Jeffery SM, Strohecker LA, Tremblay AS, Wu WC, Zulman DM. The Shared Health Appointments and Reciprocal Enhanced Support (SHARES) study: study protocol for a randomized trial. Trials. 2017 May 26;18(1):239. doi: 10.1186/s13063-017-1959-7. — View Citation

Kowalski CP, Veeser M, Heisler M. Formative evaluation and adaptation of pre-and early implementation of diabetes shared medical appointments to maximize sustainability and adoption. BMC Fam Pract. 2018 Jul 7;19(1):109. doi: 10.1186/s12875-018-0797-3. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Glycemic Control Glycemic control (measured by Hemoglobin A1c) in each group will be assessed by the comparison of an average of the values obtained during routine outpatient clinical practice in 6-month windows preceding baseline and following the 6 and 12-month post-enrollment evaluation periods. In addition to measuring absolute values of A1c, the investigators will also examine the change in the percentage of patients with an average A1c > 8%. 6 months and 12 months post-enrollment
Secondary Change in Systolic Blood Pressure (SBP) Systolic blood pressure (SBP) in each group will be assessed by the comparison of an average of the values obtained during routine outpatient clinical practice in 6-month windows preceding baseline and following the 6 and 12-month post-enrollment evaluation periods. In addition to measuring absolute values, the investigators will also examine the change in percentage of patients with an average SBP > 140. 6 months and 12 months post-enrollment
Secondary Insulin Starts The number of participants who are not on insulin at baseline and are started on insulin during the 6 and 12-month post-enrollment periods will be totaled and compared for the SMA group and the no intervention control group. For the no intervention control group, baseline will be the date they are identified by the data manager. For the SMA group, baseline will be the date of the first SMA. 6 months and 12 months post-enrollment
Secondary Emergency Department (ED) Visits Major utilization events (admissions, bed days of care, and outpatient visits) will be collected from electronic medical records. Outpatient visits will be limited to those clinics most likely to be impacted by the intervention (e.g., primary care visits, diabetes specialty visits, and nurse visits). 6 months and 12 months post-enrollment
Secondary Statin Starts The number of participants who are not on a statin at baseline and are started on insulin during the 6 and 12-month post-enrollment periods will be totaled and compared for the SMA group and the no intervention control group. For the no intervention control group, baseline will be the date they are identified by the data manager. For the SMA group, baseline will be the date of the first SMA. 6 months and 12 months post-enrollment
Secondary Change in Number of Classes of Anti-hypertensive Meds Change in antihypertensive use (number of classes of prescribed anti-hypertensives) in each group will be assessed at baseline and following the 6 and 12-month post-enrollment evaluation periods. For the no intervention control group, baseline will be the date they are identified by the data manager. For the SMA group, baseline will be the date of the first SMA. 6 months and 12 months post-enrollment
Secondary Change in Patient-reported Satisfaction With VA Care Patients' satisfaction with VA care will be assessed through surveys at baseline and 6 and 12 months post-enrollment for the SMA group. The following relates to the scale used:
Scale name: VA Healthcare Satisfaction Scale Scale ranges: 1-6 (Strongly Disagree=1, Disagree=2, Slightly Disagree=3, Slightly Agree=4, Agree=5, Strongly Agree=6) Direction of range: Higher score indicates a better outcome
6 months and 12 months post-enrollment
Secondary Change in Patient-reported Diabetes Distress Patients' level of diabetes distress will be assessed through surveys at baseline and 6 and 12 months post-enrollment for the SMA group. The following relates to the scale used:
Scale name: Diabetes Distress Scale Scale ranges: 1-5 (Not a Problem=1, Minor Problem=2, Moderate Problem=3, Somewhat Serious Problem=4, Serious Problem=5) Direction of range: Lower score indicates a better outcome
6 months and 12 months post-enrollment
Secondary Change in Patient-reported Degree of Diabetes Support Patients' degree of diabetes support will be assessed through surveys at baseline and 6 and 12 months post-enrollment for the SMA group. The following relates to the scale used:
Scale name: Diabetes Support Scale Scale ranges: 1-6 (Strongly Disagree=1, Disagree=2, Slightly Disagree=3, Slightly Agree=4, Agree=5, Strongly Agree=6) Direction of range: Higher score indicates a better outcome
6 months and 12 months post-enrollment
Secondary Change in Patient-reported Degree of Self-Efficacy Patients' degree of self-efficacy will be assessed through surveys at baseline and 6 and 12 months post-enrollment for the SMA group. The following relates to the scale used:
Scale name: Williams Self-Efficacy Scale Scale ranges: 1-6 (Strongly Disagree=1, Disagree=2, Slightly Disagree=3, Slightly Agree=4, Agree=5, Strongly Agree=6) Direction of range: Higher score indicates a better outcome
6 months and 12 months post-enrollment
Secondary Hospitalizations Major utilization events (admissions, bed days of care, and outpatient visits) will be collected from electronic medical records. Outpatient visits will be limited to those clinics most likely to be impacted by the intervention (e.g., primary care visits, diabetes specialty visits, and nurse visits). 6 months and 12 months post-enrollment
Secondary Length of Hospitalizations Major utilization events (admissions, bed days of care, and outpatient visits) will be collected from electronic medical records. Outpatient visits will be limited to those clinics most likely to be impacted by the intervention (e.g., primary care visits, diabetes specialty visits, and nurse visits). 6 months and 12 months post-enrollment
Secondary PCP Visits Major utilization events (admissions, bed days of care, and outpatient visits) will be collected from electronic medical records. Outpatient visits will be limited to those clinics most likely to be impacted by the intervention (e.g., primary care visits, diabetes specialty visits, and nurse visits). 6 months and 12 months post-enrollment
Secondary Nurse Case Manager Visits Major utilization events (admissions, bed days of care, and outpatient visits) will be collected from electronic medical records. Outpatient visits will be limited to those clinics most likely to be impacted by the intervention (e.g., primary care visits, diabetes specialty visits, and nurse visits). 6 months and 12 months post-enrollment
Secondary Endocrinology Visits Major utilization events (admissions, bed days of care, and outpatient visits) will be collected from electronic medical records. Outpatient visits will be limited to those clinics most likely to be impacted by the intervention (e.g., primary care visits, diabetes specialty visits, and nurse visits). 6 months and 12 months post-enrollment
See also
  Status Clinical Trial Phase
Completed NCT03572166 - Use of Copeptin Measurement After Arginine Infusion for the Differential Diagnosis of Diabetes Insipidus - the CARGOx Study N/A
Completed NCT04550520 - Copeptin After a Subcutaneous Stimulation With Glucagon in Adults N/A
Terminated NCT02460354 - Metformin and Congenital Nephrogenic Diabetes Insipidus Phase 1
Completed NCT02523001 - Effect of Statin Treatment on Urinary AQP2 (uAQP2/01) N/A
Active, not recruiting NCT04351945 - Endocrine Changes and Their Correction in Heart and Lung Transplant Recipients and Donors
Completed NCT00757276 - Copeptin in the Diagnosis and Differential Diagnosis of Diabetes Insipidus. The CoSIP-Study N/A
Completed NCT01940614 - Use of Copeptin in Diabetes Insipidus
Recruiting NCT02841553 - Wolfram Syndrome and WFS1-related Disorders International Registry and Clinical Study
Not yet recruiting NCT06368817 - A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma Phase 2
Completed NCT04648137 - Circulating Oxytocin Changes in Response to the Oxytocin System Stimulator MDMA in Patients With Diabetes Insipidus and Healthy Controls N/A
Active, not recruiting NCT00004364 - Study of Novel Types of Familial Diabetes Insipidus N/A
Completed NCT00004363 - Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus N/A
Completed NCT02455414 - Tracking Neurodegeneration in Early Wolfram Syndrome